Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps

doi:10.1093/infdis/jiz245

Editorial

. 2020 Jan 14;221(3):337-339.

doi: 10.1093/infdis/jiz245.

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps

Larisa V Gubareva¹, Alicia M Fry¹

Affiliations

PMID: 31309982
PMCID: PMC9012239
DOI: 10.1093/infdis/jiz245

Editorial

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps

Larisa V Gubareva et al. J Infect Dis. 2020.

. 2020 Jan 14;221(3):337-339.

doi: 10.1093/infdis/jiz245.

Authors

Larisa V Gubareva¹, Alicia M Fry¹

Affiliation

¹ Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

PMID: 31309982
PMCID: PMC9012239
DOI: 10.1093/infdis/jiz245

No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Both authors: No reported conflicts. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment on

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Uehara T, et al. J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244. J Infect Dis. 2020. PMID: 31309975 Clinical Trial.

Cited by

Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019.
Mengual-Chuliá B, Alonso-Cordero A, Cano L, Mosquera MDM, de Molina P, Vendrell R, Reyes-Prieto M, Jané M, Torner N, Martínez AI, Vila J, Díez-Domingo J, Marcos MÁ, López-Labrador FX. Mengual-Chuliá B, et al. Antimicrob Agents Chemother. 2021 May 18;65(6):e02718-20. doi: 10.1128/AAC.02718-20. Print 2021 May 18. Antimicrob Agents Chemother. 2021. PMID: 33782005 Free PMC article.
Structure-Based Design of Potent Iminosugar Inhibitors of Endoplasmic Reticulum α-Glucosidase I with Anti-SARS-CoV-2 Activity.
Karade SS, Franco EJ, Rojas AC, Hanrahan KC, Kolesnikov A, Yu W, MacKerell AD Jr, Hill DC, Weber DJ, Brown AN, Treston AM, Mariuzza RA. Karade SS, et al. J Med Chem. 2023 Feb 23;66(4):2744-2760. doi: 10.1021/acs.jmedchem.2c01750. Epub 2023 Feb 10. J Med Chem. 2023. PMID: 36762932 Free PMC article.
Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice.
Jones WA, Castro RC, Masters HL 3rd, Carrico R. Jones WA, et al. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec;5(6):974-991. doi: 10.1016/j.mayocpiqo.2021.07.005. Epub 2021 Aug 14. Mayo Clin Proc Innov Qual Outcomes. 2021. PMID: 34414356 Free PMC article. Review.
Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A.
Qiu C, Cheng F, Ye X, Wu Z, Ning H, Liu S, Wu L, Zhang Y, Shi J, Jiang X. Qiu C, et al. Front Med (Lausanne). 2024 Apr 5;11:1339368. doi: 10.3389/fmed.2024.1339368. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38646560 Free PMC article.
Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study.
Hsieh YH, Dugas AF, LoVecchio F, McBryde B, Ricketts EP, Saliba-Shaw K, Rothman RE. Hsieh YH, et al. Influenza Other Respir Viruses. 2021 Jan;15(1):121-131. doi: 10.1111/irv.12794. Epub 2020 Oct 2. Influenza Other Respir Viruses. 2021. PMID: 33006445 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. https://www.hcvguidelines.org/. Accessed 2 May 2019.
1. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed 2 May 2019.
1. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019; 32:176–86. - PMC - PubMed
1. Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol 2016; 18:126–34. - PubMed
1. Uehara THF, Kawaguchi K, Omoto S, et al. Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2019. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. https://www.hcvguidelines.org/. Accessed 2 May 2019.

[2] Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. https://www.hcvguidelines.org/. Accessed 2 May 2019.

[3] U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed 2 May 2019.

[4] U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed 2 May 2019.

[5] Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019; 32:176–86. - PMC - PubMed

[6] Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019; 32:176–86. - PMC - PubMed

[7] Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol 2016; 18:126–34. - PubMed

[8] Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol 2016; 18:126–34. - PubMed

[9] Uehara THF, Kawaguchi K, Omoto S, et al. Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2019. - PubMed

[10] Uehara THF, Kawaguchi K, Omoto S, et al. Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2019. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps

Affiliation

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps

Authors

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical